^
Association details:
| Biomarker: | CD19 expression |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft
Published date:
02/04/2021
Excerpt:
The subcutaneous tumor models were constructed using human chronic myelogenous leukemia cells expressing CD19 (K562-CD19) and human prostate cancer cells expressing PSCA (PC3-PSCA), and treated with CD19/△PD-1 CAR-T and PSCA/△PD-1 CAR-T cells, respectively. The tumor volumes significantly reduced within one week, indicating the good tumor growth inhibitory effect of △PD-1 CAR-T cells. Mice injected with △PD-1 CAR-T cells showed a significantly prolonged survival time compared to those with normal CAR-T cells.
DOI:
10.1016/j.biopha.2021.111339
